Shots:
- The US FDA has granted ODD to NMD670 for treating Charcot-Marie-Tooth disease (CMT). It is small molecule that inhibits CIC-1 to enhances muscle responsiveness, improving neuromuscular transmission & restoring function
- NMD670 (PO, BID) is under P-IIa (SYNAPSE-CMT) evaluation for its efficacy, safety & tolerability in adults (n=80) with CMT1 or CMT2 subtype for over 21 days across the US & EU. It will assess changes in 6-minute walk test (6MWT), time to complete the 10-meter walk/run test (10MW/R) & time to complete timed-up-and-go test (TUG)
- NMD Pharma is also conducting three P-II global trials of NMD670 for spinal muscular atrophy (SMA) type 3, gMG & CMT, with data expected between H2’25 & H1’26
Ref: NMD Pharma| Image: NMD Pharma
Related News:- HUTCHMED Reports the NMPA’s NDA Acceptance of Orpathys Plus Tagrisso with Priority Review for EGFR-Mutated NSCLC with MET Amplification
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
